[131ι]-Μετα-Ιωδοβενζυλογουανιδίνη Για Διαγνωστικούσ Σκοπούσ Ge Healthcare

Iobenguane (131i) is a radiopharmaceutical used for diagnostic imaging in neuroendocrine tumor detection. It targets cells with norepinephrine transporter systems. This EU-sourced agent supports precise imaging for cancer evaluation. Short version: Iobenguane (131i) diagnostic imaging agent for neuroendocrine tumors, EU-sourced.

Iobenguane (131i) is primarily used in diagnostic imaging to detect neuroendocrine tumors, including pheochromocytomas and neuroblastomas. It helps identify tumors with norepinephrine transporter systems by emitting gamma radiation for imaging. This agent is also used in evaluating metastatic disease and assessing treatment response in certain cancers. It is not intended for therapeutic purposes.

After intravenous administration, Iobenguane (131i) distributes in the body and localizes in tissues with norepinephrine transporter systems. The radiolabeled compound emits gamma rays, which are detected by imaging equipment to produce diagnostic images. Patients may experience mild discomfort at the injection site or transient effects such as nausea, though these are not common.

Iobenguane (131i) should be handled by trained medical professionals in a controlled clinical setting. Pregnant or breastfeeding individuals should avoid exposure due to radiation risks. Patients with known allergies to iodine or previous adverse reactions to similar agents should inform their healthcare provider. Hydration and urinary frequency are recommended post-administration to aid clearance.

Certain medications, such as tricyclic antidepressants, sympathomimetics, and antipsychotics, may interfere with the uptake of Iobenguane (131i). Patients should disclose all current medications to their healthcare provider before administration. Alcohol and other substances are generally avoided during the imaging process to prevent interference with results.